Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-7
Publisher
Informa UK Limited
Online
2021-12-23
DOI
10.1080/13543784.2022.2020248
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of RSV Fusion Protein Interaction Domains on the Virus Receptor, Nucleolin
- (2021) Peter Mastrangelo et al. Viruses-Basel
- Emerging small and large molecule therapeutics for respiratory syncytial virus
- (2020) Harrison C. Bergeron et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries
- (2020) Xiao Li et al. BMC Medicine
- Up-to-date role of biologics in the management of respiratory syncytial virus
- (2020) Seyhan Boyoglu-Barnum et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
- (2020) M. Pamela Griffin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
- (2020) Eric A F Simões et al. CLINICAL INFECTIOUS DISEASES
- Global molecular epidemiology of RSV from the 2017-2018 INFORM-RSV study
- (2020) David E. Tabor et al. JOURNAL OF CLINICAL MICROBIOLOGY
- National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study
- (2020) You Li et al. Lancet Respiratory Medicine
- Respiratory syncytial virus entry and how to block it
- (2019) Michael B. Battles et al. NATURE REVIEWS MICROBIOLOGY
- Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis
- (2019) Ting Shi et al. JOURNAL OF INFECTIOUS DISEASES
- Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
- (2019) Jessica Marcandalli et al. CELL
- Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
- (2019) Kevin O. Saunders Frontiers in Immunology
- CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung
- (2019) Christopher S. Anderson et al. PEDIATRIC RESEARCH
- Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority
- (2018) Bosco Paes AMERICAN JOURNAL OF PERINATOLOGY
- Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
- (2018) Hayat Caidi et al. ANTIVIRAL RESEARCH
- Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches
- (2018) Sara A. Taleb et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity
- (2018) Stephanie N. Hicks et al. JOURNAL OF VIROLOGY
- The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
- (2018) Natalie I Mazur et al. LANCET INFECTIOUS DISEASES
- Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
- (2018) Joseph B. Domachowske et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Molecular epidemiology of respiratory syncytial virus
- (2018) Krisna N.A. Pangesti et al. REVIEWS IN MEDICAL VIROLOGY
- Clinical Potential of Prefusion RSV F-specific Antibodies
- (2018) Iebe Rossey et al. TRENDS IN MICROBIOLOGY
- Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial
- (2018) Nienke M Scheltema et al. Lancet Respiratory Medicine
- Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem
- (2017) Ralph A. Tripp et al. JOURNAL OF VIROLOGY
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
- (2017) Qing Zhu et al. Science Translational Medicine
- Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
- (2017) Anne M. Hause et al. PLoS One
- Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
- (2017) Mallika Sastry et al. PLoS One
- Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
- (2016) M. Pamela Griffin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life
- (2016) A. KUTSAYA et al. EPIDEMIOLOGY AND INFECTION
- Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis
- (2016) Renato T. Stein et al. PEDIATRIC PULMONOLOGY
- Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop
- (2016) Jeffrey N. Roberts et al. VACCINE
- Respiratory syncytial virus in infants
- (2015) Flor M. Munoz CURRENT OPINION IN INFECTIOUS DISEASES
- CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells
- (2015) Tatiana Chirkova et al. JOURNAL OF GENERAL VIROLOGY
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
- (2015) Anders Krarup et al. Nature Communications
- Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures
- (2015) Sara M. Johnson et al. PLoS Pathogens
- CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner
- (2015) Kwang-Il Jeong et al. PLoS One
- Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
- (2014) PEDIATRICS
- Respiratory Syncytial Virus—A Comprehensive Review
- (2013) Andrea T. Borchers et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses
- (2013) T. Chirkova et al. JOURNAL OF VIROLOGY
- Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness
- (2013) Octavio Ramilo et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Respiratory Syncytial Virus-Associated Hospitalizations Among Children Less Than 24 Months of Age
- (2013) C. B. Hall et al. PEDIATRICS
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
- (2013) J. S. McLellan et al. SCIENCE
- Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
- (2013) J. S. McLellan et al. SCIENCE
- Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein
- (2013) Zhiwu Sun et al. Viruses-Basel
- Advances in and the potential of vaccines for respiratory syncytial virus
- (2013) Patricia A Jorquera et al. Expert Review of Respiratory Medicine
- The Secreted G Protein of Human Respiratory Syncytial Virus Antagonizes Antibody-Mediated Restriction of Replication Involving Macrophages and Complement
- (2012) A. Bukreyev et al. JOURNAL OF VIROLOGY
- A review of cost–effectiveness of palivizumab for respiratory syncytial virus
- (2012) Julia M Hussman et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Identification of nucleolin as a cellular receptor for human respiratory syncytial virus
- (2011) Farnoosh Tayyari et al. NATURE MEDICINE
- Management of RSV infections in adult recipients of hematopoietic stem cell transplantation
- (2010) J. N. Shah et al. BLOOD
- Therapeutic targeting of respiratory syncytial virus G-protein
- (2010) Lawrence M Kauvar et al. Immunotherapy
- The cost effectiveness of palivizumab: a systematic review of the evidence
- (2010) Kelly A. Smart et al. JOURNAL OF MEDICAL ECONOMICS
- Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice
- (2009) W. Zhang et al. JOURNAL OF VIROLOGY
- Generation of stable monoclonal antibody–producing B cell receptor–positive human memory B cells by genetic programming
- (2009) Mark J Kwakkenbos et al. NATURE MEDICINE
- Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction
- (2008) M. Shingai et al. INTERNATIONAL IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now